What question did this study set out to answer?

The aim is to evaluate the prevalence of albuminuria testing and disease-modifying therapies in CKM disease patients.

Large-scale AI analysis reveals missed opportunities in albuminuria testing and disease-modifying therapy implementation

View Full Paper

Ask AI

Bookmark

Authors

This retrospective cohort study assesses albuminuria testing in CKM disease, indicating significant underdiagnosis and therapy gaps.

The aim is to evaluate the prevalence of albuminuria testing and disease-modifying therapies in CKM disease patients.
Conducted a retrospective cohort study at a cardiology department from 2019 to 2024.
Utilized an AI-driven platform for data extraction on patient records.
Defined albuminuria with a urine albumin-to-creatinine ratio of ≥30 mg/g.
Employed a weighted logistic regression model to estimate prevalence in untested patients.
Only 8.9% of patients had documented UACR testing, with 46.4% testing positive for albuminuria.
Highest testing rates in high-risk groups: 29.9% in diabetes, 21.7% in heart failure, and 13.7% in hypertension.
The estimated prevalence of undiagnosed albuminuria was 36.6%, peaking at 70.0% in patients with eGFR <30 mL/min/1.73m2.
Low usage of disease-modifying therapies among those with confirmed albuminuria, with only 43.0% on renin–angiotensin inhibitors.

Es et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark